No Picture
Boston Cambridge Biotech Trending News

BeiGene Announces Acceptance of Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia with Breakthrough Therapy Designation

CAMBRIDGE, Mass. & BEIJING–(BUSINESS WIRE)—- $BGNE #BGNE–BeiGene announces an sNDA for BRUKINSA in first-line chronic lymphocytic leukemia has been accepted in China with breakthrough therapy designation. Click here to view original post

No Picture
Boston Cambridge Biotech Trending News

ReForm Biologics Changes Name to Comera Life Sciences

WOBURN, Mass.–(BUSINESS WIRE)–ReForm Biologics, Inc., a company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced that the company has changed its name to Comera Life Sciences, […]

No Picture
Boston Cambridge Biotech Trending News

Under pressure, Biogen outlines ambitious diversity goals for Aduhelm study — but the Medicare fight is still on

Biogen, facing renewed criticism for a lack of diversity in its Alzheimer’s clinical trials, announced on Thursday a new commitment: At least 18% of the participants in the FDA-mandated confirmatory study for its controversial drug […]

No Picture
Boston Cambridge Biotech Trending News

Deciphera Pharmaceuticals Presents Results from the INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session

WALTHAM, Mass.–(BUSINESS WIRE)–Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, announced the presentation of results from the INTRIGUE Phase 3 study of QINLOCK […]

No Picture
Boston Cambridge Biotech Trending News

HEMANEXT ONE® BECOMES FIRST BLOOD PROCESSING AND STORAGE SYSTEM TO RECEIVE STANDARDS-COMPLIANT SEAL FROM AABB

LEXINGTON, Mass.: LEXINGTON, Mass., Jan. 24, 2022 /PRNewswire/ — Hemanext Inc. today announced that Hemanext ONE®, its innovative blood processing and storage system, has been recognized by the Association for the Advancement of Blood & […]

No Picture
Boston Cambridge Biotech Trending News

BeiGene Announces Positive Findings from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy in First-Line Gastric or Gastroesophageal Junction Cancer

CAMBRIDGE, Mass. & BEIJING–(BUSINESS WIRE)—- $BGNE #BGNE–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today […]

No Picture
Boston Cambridge Biotech Trending News

Critics push back on Alzheimer’s Association ad blitz to get Medicare to change its Aduhelm ruling: ‘Dead wrong’

The latest Alzheimer’s Association advertising campaign encourages people to fight. Not against the disease or for more research or treatments, but against the Centers for Medicare and Medicaid Services. More specifically, CMS’ recent reimbursement decision […]

No Picture
Boston Cambridge Biotech Trending News

Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis, […]